about
Gene organization and alternative splicing of human prohormone convertase PC8Subtilisin-like proprotein convertases, PACE4 and PC8, as well as furin, are endogenous proalbumin convertases in HepG2 cellsThe COOH-terminus of parathyroid hormone-related protein (PTHrP) interacts with beta-arrestin 1BCalcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytesPTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function.Molecular stress-inducing compounds increase osteoclast formation in a heat shock factor 1 protein-dependent mannerCharacterization of sugar binding by osteoclast inhibitory lectin.Zinc finger protein 467 is a novel regulator of osteoblast and adipocyte commitment.Generation and analysis of Siah2 mutant mice.The mouse NKR-P1B:Clr-b recognition system is a negative regulator of innate immune responses.Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formationMechanisms involved in skeletal anabolic therapies.Impact of cytokines and T lymphocytes upon osteoclast differentiation and function.Osteoclast inhibitory lectin, an immune cell product that is required for normal bone physiology in vivo.Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor.Thalassemia bone disease: a 19-year longitudinal analysis.Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.Bone Disease in Thalassemia: A Molecular and Clinical Overview.Genetic investigation of MHC-independent missing-self recognition by mouse NK cells using an in vivo bone marrow transplantation model.Osteoclast formation elicited by interleukin-33 stimulation is dependent upon the type of osteoclast progenitor.BMP-2 regulation of PTHrP and osteoclastogenic factors during osteoblast differentiation of C2C12 cells.Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo.RARγ is a negative regulator of osteoclastogenesis.Dexamethasone regulation of parathyroid hormone-related protein (PTHrP) expression in a squamous cancer cell line.Melphalan modifies the bone microenvironment by enhancing osteoclast formation.Nuclear transport of parathyroid hormone (PTH)-related protein is dependent on microtubules.Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis.Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.Osteopenia in Siah1a mutant mice.Urolithiasis is prevalent and associated with reduced bone mineral density in β-thalassaemia major.IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice.Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.Cardiotrophin-1 Is an Osteoclast-Derived Stimulus of Bone Formation Required for Normal Bone RemodelingDeferasirox at therapeutic doses is associated with dose-dependent hypercalciuria
P50
Q24531313-39669DF3-A365-4C58-A098-9ADC61CC9D0BQ28137925-33B54614-62F3-484E-8C28-C32BD38FD21AQ28200852-7F0B6D29-AAF1-41BC-88E3-B85A1F0597DBQ28274381-49841221-5385-47D1-8A10-301D66B86189Q31122542-4050104C-EF0F-46FF-8063-FCA89C10AC10Q33552875-EB2D104E-A4C3-44FD-A8DB-11FB0B118E6AQ33676779-BC56F387-9F1B-4E0E-8C2C-42DCACC360E7Q34318289-42FF82F5-9C34-4AA0-95A9-970121AD0D17Q34575607-435BA402-9CBE-4066-A661-17495D7CD23DQ34986884-86E18367-E7AA-4CA0-9113-8D45261CDEFDQ35252639-B7479F90-36D9-4148-A931-90E91851F713Q36377004-A8F03DFC-72B0-4F23-86DE-A7C1FC02F126Q36532582-8671535D-508A-4644-AEA9-E206AD24DD6EQ36768424-6887E281-AB7E-4C8E-968B-EDC2CECC580CQ37142713-141FD6EA-511F-4A7C-9EDC-4A269915B95BQ37377903-91F3A8B0-8A52-41AC-BBAA-47DB3672EAB2Q38206984-0BBEB5E4-EFF6-40FB-ABBC-434CFC6CB6DAQ38296222-8B4C7932-11DE-465A-9E26-85DA4101466BQ38866904-094249DC-AD58-4F4F-83DA-D87F9AA233C7Q38909779-98364BE8-7D76-425B-85BD-52869E606F5EQ38933799-5CC2EEBB-640E-4B51-AE6F-9998F5AE2B6BQ40016973-454649A5-DE32-4F5E-B726-8FF24E0B4E30Q40296427-8A1561A0-3829-4E09-9D07-21ADBE6A7F5EQ40505552-C26E402D-4FAB-4FED-A907-BF926E056630Q40538587-38AB8A8B-49A4-4137-A100-27374AE2CDA1Q40733657-76CA75B1-2CE1-45E7-AF0B-45BDF0D18C29Q41175656-8083FC73-59C8-4D54-AE5D-A14B2EBDDCC0Q41468768-6D63C766-9B48-4137-8AF0-E1FF127154D1Q42366597-1DD9148C-79FB-4545-82F3-376661E2ADDAQ43871383-95175252-75B8-469D-A4BD-77698098CEF2Q44973887-B5EBB3A2-02E4-4D6F-92EF-35C7178E9BAEQ45732833-C8F4C971-8E89-4884-85DC-01EE590031D8Q47657801-7D377F1E-4070-49E6-BDE0-16C1465DFE86Q48054378-EE97C790-85CA-44A7-825B-2B1FB6AC0B28Q51680495-B30EE455-3F93-4D38-B703-2D7F0C6F83B3Q52172979-A78F710F-0B09-4EBF-8A05-01FF94865B81Q54041247-70DB4671-AB2A-422A-AFD2-A4B8C313628EQ54452122-44174D9C-401B-4623-B106-3D515996C662Q57265515-00E06885-2429-4CFE-8FAA-DD6DC3697F87Q58433521-F4F3230D-870E-4AAB-BC46-9A5CD3100D7F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Matthew T Gillespie
@ast
Matthew T Gillespie
@en
Matthew T Gillespie
@es
Matthew T Gillespie
@nl
type
label
Matthew T Gillespie
@ast
Matthew T Gillespie
@en
Matthew T Gillespie
@es
Matthew T Gillespie
@nl
prefLabel
Matthew T Gillespie
@ast
Matthew T Gillespie
@en
Matthew T Gillespie
@es
Matthew T Gillespie
@nl
P106
P1153
7102623338
P31
P496
0000-0001-6543-8909